On February 24, 2023 Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), reported that it will be attending the 2nd GPCR-Targeted Drug Discovery Summit in Boston from February 21st-23rd (Press release, Orion Biotechnology, FEB 24, 2023, View Source [SID1234627680]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Oliver Hartley, Orion’s Vice President of Drug Discovery, will be presenting on February 23rd at 11:15 AM EST. Dr Hartley’s presentation will explore the power of Orion’s PROcisionXTM discovery platform in unlocking the therapeutic potential of small protein GPCRs. Additionally, Dr. Hartley will discuss Orion’s diverse portfolio of GPCR-targeted therapeutics.

Commenting on his presentation, Dr. Hartley said "I’m pleased to be presenting Orion’s breakthrough technology at the GPCR-Targeted Drug Discovery Summit. This event is an excellent opportunity for us to connect with the GPCR industry and provide an update on our ongoing activities, including the development of our best-in-class CCR2 antagonist, OB-004.

If you’d like to learn more about Orion’s perspective on GPCR drug discovery, you can read their whitepaper on Fierce Biotech.